Ultrasound screening for thyroid nodules and cancer in individuals with family history of thyroid cancer: a micro-costing approach.
Cost-effectiveness
Differentiated thyroid cancer
Familial non-medullary thyroid cancer
Thyroid nodule
Journal
Journal of endocrinological investigation
ISSN: 1720-8386
Titre abrégé: J Endocrinol Invest
Pays: Italy
ID NLM: 7806594
Informations de publication
Date de publication:
Nov 2023
Nov 2023
Historique:
received:
12
01
2023
accepted:
02
04
2023
medline:
9
10
2023
pubmed:
14
4
2023
entrez:
13
4
2023
Statut:
ppublish
Résumé
Screening programs that target healthy populations are an important tool for identifying unrecognized, asymptomatic disease. However, ultrasound screening for thyroid cancer has no obvious advantage in terms of cost-effectiveness in asymptomatic adults. There is far less consensus (and data) on the indications for screening in high-risk individuals. The aim of the study was to estimate the costs of ultrasound screening for individuals with first-degree family history of thyroid cancer. We conducted a prospective cross-sectional study from January 1, 2009 through December 31, 2018 in the Thyroid Cancer Outpatient Clinic of a large teaching hospital in Rome, Italy. We estimated the costs of an ultrasound screening protocol using the micro-costing bottom-up method. For individuals without thyroid nodules, the screening examination had an estimated cost of €66.21 per screenee. For those found to have unsuspicious nodules, the estimated cost rose to €119.52 per screenee, owing to the addition of thyroid function tests. The estimated cost of screening for a subject with newly diagnosed nodules that were submitted to cytology was €259.89. The total cost of screening for the entire population of 1176 individuals was € 118,133.85. The total expenditure to confirm a single thyroid cancer diagnosis was €10,598.71. A sonographic screening implies a significant direct expenditure and is likely to detect a very large number of individuals with benign nodules (more than 45 asymptomatic individuals are diagnosed with a thyroid nodule for each newly detected cancer case), whose long-term follow-up will further increase healthcare costs.
Identifiants
pubmed: 37052872
doi: 10.1007/s40618-023-02087-3
pii: 10.1007/s40618-023-02087-3
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
2327-2330Informations de copyright
© 2023. The Author(s), under exclusive licence to Italian Society of Endocrinology (SIE).
Références
World Health Organization (2007) Cancer Control: Knowledge into Action: WHO Guide for Effective Programmes: Module 3: Early Detection. World Health Organization. Geneva
Ahn HS, Kim HJ, Welch HG (2014) Korea’s Thyroid-Cancer “Epidemic”—screening and Overdiagnosis. N Engl J Med 371:1765–1767. https://doi.org/10.1056/NEJMp1409841
doi: 10.1056/NEJMp1409841
pubmed: 25372084
Ramundo V, Sponziello M, Falcone R et al (2020) Low-risk papillary thyroid microcarcinoma: optimal management toward a more conservative approach. J Surg Oncol 121:958–963. https://doi.org/10.1002/jso.25848
doi: 10.1002/jso.25848
pubmed: 32189352
Yang N, Yang H, Guo JJ et al (2021) Cost-Effectiveness analysis of ultrasound screening for Thyroid Cancer in asymptomatic adults. Front Pub Health 9:729684. https://doi.org/10.3389/fpubh.2021.729684
doi: 10.3389/fpubh.2021.729684
US Preventive Services Task Force, Bibbins-Domingo K, Grossman DC et al (2017) Screening for Thyroid Cancer: US preventive services task force recommendation statement. JAMA 317:1882. https://doi.org/10.1001/jama.2017.4011
doi: 10.1001/jama.2017.4011
Lin JS, Bowles EJA, Williams SB, Morrison CC (2017) Screening for Thyroid Cancer: updated evidence report and systematic review for the US preventive services task force. JAMA 317:1888. https://doi.org/10.1001/jama.2017.0562
doi: 10.1001/jama.2017.0562
pubmed: 28492904
Lamartina L, Grani G, Durante C et al (2020) Screening for differentiated thyroid cancer in selected populations. Lancet Diabetes Endocrinol 8:81–88. https://doi.org/10.1016/S2213-8587(19)30324-9
doi: 10.1016/S2213-8587(19)30324-9
pubmed: 31591051
Haugen BR, Alexander EK, Bible KC et al (2016) 2015 American Thyroid association management guidelines for adult patients with Thyroid Nodules and differentiated Thyroid Cancer: the American Thyroid association guidelines task force on Thyroid Nodules and differentiated Thyroid Cancer. Thyroid 26:1–133. https://doi.org/10.1089/thy.2015.0020
doi: 10.1089/thy.2015.0020
pubmed: 26462967
pmcid: 4739132
Filetti S, Durante C, Hartl D et al (2019) Thyroid cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up†. Ann Oncol 30:1856–1883. https://doi.org/10.1093/annonc/mdz400
doi: 10.1093/annonc/mdz400
pubmed: 31549998
Grani G, Lamartina L, Montesano T et al (2022) (2022) Prevalence of thyroid nodules and thyroid cancer in individuals with a first-degree family history of non-medullary thyroid cancer: a cross-sectional study based on sonographic screening. Thyroid 32(11):1392–1401. https://doi.org/10.1089/thy.2022.0253
doi: 10.1089/thy.2022.0253
pubmed: 36097761
Xu X, Grossetta Nardini HK, Ruger JP (2014) Micro-costing studies in the health and medical literature: protocol for a systematic review. Syst Rev 3:47. https://doi.org/10.1186/2046-4053-3-47
doi: 10.1186/2046-4053-3-47
pubmed: 24887208
pmcid: 4036677
Tarricone R (2006) Cost-of-illness analysis. Health Policy 77:51–63. https://doi.org/10.1016/j.healthpol.2005.07.016
doi: 10.1016/j.healthpol.2005.07.016
pubmed: 16139925
Spandonaro F, Cerbo M, Ratti M et al. Progetto di ricerca finalizzata: Valutazione sperimentale costo efficacia delle linee guida su screening, diagnosi precoce e trattamento multidisciplinare del cancro del colon retto. https://www.agenas.gov.it/images/agenas/ricerca/agenas_ccm_corrente_finalizzata/innovazione_hta/2004/Sintesi_progetto_di_ricerca_finalizzata_colon_retto.pdf . Accessed 12 Apr 2023
Hyun MK, Kim JH, Kwon JW (2019) Incidence of thyroid cancer and medical cost among patients with newly diagnosed thyroid nodules in Korea: a retrospective cohort study using nationwide data. J Cancer Res Ther 15:676–680. https://doi.org/10.4103/0973-1482.204895
doi: 10.4103/0973-1482.204895
pubmed: 31169239
Uppal N, Cunningham Nee Lubitz C, James B (2022) The cost and financial burden of Thyroid Cancer on patients in the US: a review and directions for future research. JAMA Otolaryngol Head Neck Surg 148:568–575. https://doi.org/10.1001/jamaoto.2022.0660
doi: 10.1001/jamaoto.2022.0660
pubmed: 35511135
Tumino D, Grani G, Di Stefano M et al (2019) Nodular Thyroid Disease in the Era of precision medicine. Front Endocrinol (Lausanne) 10:907. https://doi.org/10.3389/fendo.2019.00907
doi: 10.3389/fendo.2019.00907
pubmed: 32038482
Durante C, Costante G, Lucisano G et al (2015) The natural history of benign Thyroid Nodules. JAMA 313:926. https://doi.org/10.1001/jama.2015.0956
doi: 10.1001/jama.2015.0956
pubmed: 25734734
Grani G, Lamartina L, Biffoni M et al (2018) Sonographically estimated risks of malignancy for Thyroid Nodules computed with five standard classification systems: changes over time and their relation to malignancy. Thyroid 28:1190–1197. https://doi.org/10.1089/thy.2018.0178
doi: 10.1089/thy.2018.0178
pubmed: 30105949
Colbeth HL, Genere N, Hall CB et al (2020) Evaluation of medical surveillance and incidence of post-September 11, 2001, Thyroid Cancer in world trade center-exposed firefighters and emergency medical service workers. JAMA Intern Med 180:888. https://doi.org/10.1001/jamainternmed.2020.0950
doi: 10.1001/jamainternmed.2020.0950
pubmed: 32310290
pmcid: 7171583
Durante C, Grani G (2020) Clinically silent Thyroid Cancers: drop those needles and scalpels! J Clin Endocrinol Metab 105:e889–e890. https://doi.org/10.1210/clinem/dgz129
doi: 10.1210/clinem/dgz129